the compensation committee of BioMarin's board of directors approved the grant to 27 employees of stock options to …
The market starts on another down day as the Dog Days of August persist in whittling away the positive backdrop of the …
... play on BioMarin Pharmaceutical (BMRN), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jan 19, 2018 $80 covered call for a net debit in the $77.86 area. That is also the break-even stock price for the …
BioMarin Pharmaceutical, Inc. (Nasdaq:BMRN), a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes, will visit the Nasdaq MarketSite in Times Square in …
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced the …
BioMarin Pharmaceutical Inc.'s stock fell 2.5% in premarket trade Thursday, after the biotechnology company said the Food and Drug Administration would not be approving its new drug application (NDA) for its muscular dystrophy …
The Cowen price target for the stock is $46. The Thomson/First Call consensus is at $38.43. The stock closed Monday at $31.10. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) develops and commercializes innovative biopharmaceuticals …
SAN RAFAEL, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today an offering, subject to market and other conditions, of 7,250,000 shares of its common stock in an underwritten …
Spark Therapeutics, the Philadelphia-based company that makes the treatment, and Pfizer, which now is working with Spark on it, paid for the study, and some of the …